(Circulation. 2001;103:3150.)
© 2001 American Heart Association, Inc.
Current Perspective |
From the University of Texas School of Public Health, Houston, Tex.
Correspondence to Lemuel A. Moyé, MD, PhD, University of Texas School of Public Health, RAS Building E-815, 1200 Herman Pressler, Houston, TX 77030. E-mail lmoye{at}utsph.sph.uth.tmc.edu
AbstractAdvances in computing have combined with the rapid dissemination of treatment discoveries for diseases of public health importance to create pressure for accelerated promulgation of promising research results to the medical community. The 2 recent examples of the US Carvedilol Heart Failure program and the Evaluation of Losartan In the Elderly (ELITE) study demonstrate the importance of the prospective nature of research design, as well as the consequences of its abandonment. This article explains in nonmathematical terms the rationale for the tenet "first say what you will do, then do what you said" in sample-based research.
Key Words: trials statistics population epidemiology
This article has been cited by other articles:
![]() |
S. S. Rathore, Y. Wang, and H. M. Krumholz Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure N. Engl. J. Med., October 31, 2002; 347(18): 1403 - 1411. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. DeMets and R. M. Califf Lessons Learned From Recent Cardiovascular Clinical Trials: Part II Circulation, August 13, 2002; 106(7): 880 - 886. [Full Text] [PDF] |
||||
![]() |
L. A. Moye and A. T.N. Tita Defending the Rationale for the Two-Tailed Test in Clinical Research Circulation, June 25, 2002; 105(25): 3062 - 3065. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |